(A) Anal Squamous Cell Carcinoma, appendix, (B) Biliary Adenocarcinoma (gallbladder or biliary tree (intrahepatic or extrahepatic cholangiocarcinoma) except Ampulla of Vater cancers) (C) Neuroendocrine Tumors (well- and moderately differentiated) of the lung, colon, (D) Endometrial Carcinoma (sarcomas and mesenchymal tumors are excluded), (E) Cervical Squamous Cell Carcinoma, excluding subjects with dMMR/MSI-H tumors., F1CDx assay), (F) Vulvar Squamous Cell Carcinoma, (G) Small Cell Lung Carcinoma, (H) Mesothelioma, (I) Thyroid Carcinoma, (J) Salivary Gland Carcinoma (sarcomas and mesenchymal tumors are excluded), OR (K) Any advanced solid tumor, or pancreas, rectum, small intestine, which is microsatellite instability (MSI)-high (MSI-H). (L) Any advanced solid tumor (including CRC) which is mismatch repair deficient (dMMR)/MSI-H in subjects from mainland China who are of Chinese descent. (M) Any advanced solid tumor that has failed at least one line of therapy and is Tumor Mutational Burden-High (TMB-H) (≥10 mut/Mb, with the exception of colorectal carcinoma (CRC)
Conditions
Brief summary
Objective Response Rate (ORR)
Detailed description
Duration of Response (DOR), Progression Free Survival (PFS), Overall Survival (OS), Percentage of Participants with Adverse Events, Percentage of Participants who Discontinued Study Intervention due to Adverse Events
Interventions
DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion
Sponsors
Merck Sharp & Dohme LLC
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate (ORR) | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of Response (DOR), Progression Free Survival (PFS), Overall Survival (OS), Percentage of Participants with Adverse Events, Percentage of Participants who Discontinued Study Intervention due to Adverse Events | — |
Countries
Denmark, France, Germany, Italy, Netherlands, Norway, Poland, Portugal, Spain
Outcome results
None listed